PPARA and melanoma: Using syngenic implantation of B16 melanoma, LLC1 lung carcinoma, and SKOV-3 ovarian cancer xenograft models, the efficiency of the tumor growth-inhibiting properties of the PPARα antagonist NXT629 has been demonstrated [62].